OR WAIT 15 SECS
NanoMab Technology has signed heads of terms with a supplier of Tungsten-188/Rhenium-188 generators, OncoBeta.
Privately held biopharmaceutical company, NanoMab Technology, has signed heads of terms with a supplier of Tungsten-188/Rhenium-188 generators, OncoBeta, it was revealed in an Oct. 27, 2020 press release.
The heads of terms outline the route toward a strategic alliance and supply agreement between the companies that will target the development of Rhenium-188 API solutions. Rhenium-188 API solutions are suitable for NanoMab’s range of nanobodies for the production of therapeutic radiopharmaceuticals.
“This is an important step for us in our development of cancer therapies,” said Dr. Hong Hoi Ting, NanoMab’s chief scientific officer, in the press release. “Ensuring that we have a global supply of Rhenium-188 is critical to our development plan and we are therefore delighted to be forming a partnership with such a high-quality company as OncoBeta.”
Nicholas H. Vetter, OncoBeta’s chief operating officer, added in the press release, “We have been impressed with NanoMab’s ambitious program to develop a range of radiopharmaceuticals for the treatment of a number of cancers. We’re delighted to work towards forming a partnership with NanoMab around the use of Rhenium-188 for further therapeutic purposes.”